NeoGenomics Inc (NEO)
Pretax margin
| Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) (ttm) | US$ in thousands | -97,097 | -107,335 | -125,508 | -139,901 | -159,342 | -178,022 | -161,568 | -47,099 | -15,076 | 36,695 | 62,087 | -29,305 | -14,056 | -19,188 | -17,919 | 2,203 | 3,645 | 2,612 | 1,198 | -1,705 |
| Revenue (ttm) | US$ in thousands | 601,638 | 580,487 | 554,336 | 529,041 | 507,523 | 493,983 | 486,680 | 484,258 | 482,622 | 482,400 | 486,504 | 451,757 | 442,254 | 425,319 | 404,547 | 419,283 | 408,830 | 378,437 | 342,861 | 308,894 |
| Pretax margin | -16.14% | -18.49% | -22.64% | -26.44% | -31.40% | -36.04% | -33.20% | -9.73% | -3.12% | 7.61% | 12.76% | -6.49% | -3.18% | -4.51% | -4.43% | 0.53% | 0.89% | 0.69% | 0.35% | -0.55% |
December 31, 2023 calculation
Pretax margin = EBT (ttm) ÷ Revenue (ttm)
= $-97,097K ÷ $601,638K
= -16.14%
Neogenomics Inc.'s pretax margin has shown a declining trend over the past eight quarters. In Q4 2023, the pretax margin improved to -16.41% from -18.67% in Q3 2023. Despite this improvement, the company has still been operating at a loss for several consecutive quarters. The highest pretax margin recorded in the last eight quarters was -9.69% in Q1 2022.
The consistent negative pretax margins suggest that Neogenomics Inc. may be experiencing challenges in controlling its operating expenses or generating sufficient revenue to cover its costs. Investors and stakeholders may monitor the company's efforts to improve operational efficiency and increase profitability to ensure long-term sustainability.